志贺菌控制性人类感染模型研究实施共识报告
志贺菌是全球发病和死亡的重要原因,主要在低资源地区影响幼儿,且抗生素耐药性日益增加,被世界卫生组织列为优先病原体。志贺菌疫苗可减少疾病负担和抗生素使用,控制性人类感染模型(CHIM)有助于疫苗早期评估和潜在许可支持。
要点
- 志贺菌CHIM可用于疫苗候选物的早期筛选和潜在许可支持。
- 不同中心的CHIM研究方法已趋统一,但仍存在实施差异。
- 本文提供志贺菌CHIM研究的统一操作程序。
核心结论
- 本文形成了一套统一的志贺菌CHIM研究实施程序。
主要发现
- 志贺菌CHIM方法在不同实施中心间已变得更统一,但仍存在一些实施差异。
临床怎么用
- 本文可作为开展志贺菌CHIM研究的统一操作参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Shigella causes morbidity and mortality worldwide, primarily affecting young children living in low-resource settings. It is also of great concern due to increasing antibiotic resistance, and is a priority organism for the World Health Organization. A Shigella vaccine would decrease the morbidity and mortality associated with shigellosis, improve child health, and decrease the need for antibiotics. Controlled human infection models (CHIMs) are useful tools in vaccine evaluation for early up- or down-selection of vaccine candidates and potentially useful in support of licensure. Over time, the methods employed in these models have become more uniform across sites performing CHIM trials, although some differences in conduct persist. In November 2017, a Shigella CHIM workshop was convened in Washington, District of Columbia. Investigators met to discuss multiple aspects of these studies, including study procedures, clinical and immunological endpoints, and shared experiences. This article serves as a uniform procedure by which to conduct Shigella CHIM studies.
引用
- Talaat KR, Bourgeois AL, Frenck RW, et al. Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies. Clin Infect Dis. 2019. PMID: 31816068. doi:10.1093/cid/ciz892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。